DoubleChecks

What was claimed

Big Pharma has now woken up to the race for a cancer vaccine. We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics; a decade of work is now coming to fruition and a vaccine cannot be created without that AI platform.

Our verdict

Needs caution

Multiple organizations have developed personalized cancer vaccines using various approaches. Peptide vaccines represent 64.8% of clinical trials, and companies like Moderna have advanced neoantigen vaccines. AI assists but is not strictly necessary for vaccine creation. While Nantomics did work on neoepitope vaccines, the broader field of neoepitope research predates 2015. Key research on mutation-specific T cells and tumor-specific mutant antigens was published in 2014, suggesting Nantomics was not the originator of this quest. (Only 1 of 3 AI systems responded.)

Assessment5 sourcesChecked Sep 7, 2026

Why this verdict

  • A vaccine cannot be created without that AI platform

    Incorrect
    One assessment reached this conclusion

  • We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics

    Misleading
    One assessment reached this conclusion

  • Big Pharma has now woken up to the race for a cancer vaccine

    Can’t verify
    One assessment reached this conclusion

  • A decade of work is now coming to fruition

    Verified
    One assessment reached this conclusion

Evidence reviewed

5 sources

Claude source is combined here.

nantomics.comnature.compubmed.ncbi.nlm.nih.govncbi.nlm.nih.govcancertreatmentreviews.com

Individual assessments

PerplexityDid not respond

Assessment summary

  • The statement contains partially accurate claims about Nantomics' work on neoepitope vaccines, but makes misleading absolute claims about necessity.
  • The critical claim that "a vaccine cannot be created without that AI platform" is demonstrably false—multiple organizations have developed personalized cancer vaccines using different approaches.
  • Additionally, neoepitope research predates the claimed 2015 start date.

Claims reviewed

A vaccine cannot be created without that AI platform

Incorrect
Multiple organizations have developed personalized cancer vaccines using various approaches. Peptide vaccines represent 64.8% of clinical trials, and companies like Moderna have advanced neoantigen vaccines. AI assists but is not strictly necessary for vaccine creation.

This claim may mislead readers without added context.

We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics

Misleading
While Nantomics did work on neoepitope vaccines, the broader field of neoepitope research predates 2015. Key research on mutation-specific T cells and tumor-specific mutant antigens was published in 2014, suggesting Nantomics was not the originator of this quest.

This claim may mislead readers without added context.

Big Pharma has now woken up to the race for a cancer vaccine

Can’t verify
While evidence shows major companies like Moderna are conducting neoantigen vaccine trials, the vague claim about 'Big Pharma waking up' cannot be precisely verified without defining what constitutes sufficient industry engagement.
ChatGPTDid not respond

Check your own claim

Paste any statement, headline, or AI answer. Independent assessments check it and compare sources.

Share this result